Compare Prudential Financial Inc (PRU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Prudential Financial Inc trades at $113.12 (market cap $39.13B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Prudential Financial Inc is far larger — about 5.2× Spyre Therapeutics Inc. Common Stock's market cap, and Prudential Financial Inc pays a 4.94% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 146 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PRU | SYRE | |
|---|---|---|
Market Cap | $39.13B | $7.52B |
Volume | 1,369,167 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $125.13 | $108.92 |
52-Week Low | $92.00 | $22.18 |
Typical Hold Time | 146 Days | 0 Days |
Enterprise Value | $67.90B | $6.52B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.49, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but fundamentally attractive valuation metrics including a P/E of 10.28 and P/S of 0.61. Recent earnings show two consecutive quarterly beats, while the company executes strategic initiatives including a $185 million Alexforbes stake sale and rebranding to Prudential Wealth Advisors.
PRU offers value investment appeal with strong profitability metrics (12.46% ROE) and dividend income potential, though facing headwinds from bearish technical trends and mixed analyst sentiment. The company's strategic focus on core businesses and cost reduction provides upside potential, while interest rate sensitivity and competitive pressures remain key monitoring points for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
